BiotechTube

Lazertinib 240 mg

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Lung Cancer

Conditions

Lung Cancer

Trial Timeline

— → —

NCT ID
NCT04829422

About Lazertinib 240 mg

Lazertinib 240 mg is a pre-clinical stage product being developed by Yuhan for Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT04829422. Target conditions include Lung Cancer.

What happened to similar drugs?

20 of 20 similar drugs in Lung Cancer were approved

Approved (20) Terminated (3) Active (0)
✅Sivelestat sodium hydrate + Sivelestat sodium hydrateOno PharmaceuticalApproved
✅Pemetrexed + CarboplatinEli LillyApproved
✅pemetrexedEli LillyApproved
✅Budesonide + SymbicortAstraZenecaApproved
✅Symbicort® total dose 400ug/12ug + Symbicort® total dose 800ug/24ug + Formoterol 24ug + BUD total dose 800ugAstraZenecaApproved
✅Osimertinib+cisplatin or carboplatin + pemetrexed EditAstraZenecaApproved
✅DurvalumabAstraZenecaApproved

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04829422Pre-clinicalCompleted

Competing Products

20 competing products in Lung Cancer

See all competitors
ProductCompanyStageHype Score
BBP-398 with nivolumabBridgeBio PharmaPhase 1
18
Pemetrexed + CarboplatinEli LillyPhase 3
40
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
27
SelpercatinibEli LillyPre-clinical
26
Pemetrexed + Cisplatin + Placebo + PemetrexedEli LillyPhase 3
40
NBTXR3NanobiotixPhase 1/2
33
PemetrexedEli LillyPre-clinical
26
pemetrexed + erlotinibEli LillyPhase 2
35
Necitumumab-Gemcitabine-CisplatinEli LillyPhase 2
27
LY3295668 ErbumineEli LillyPhase 1
29
FYB206 + FYB206 + KeytrudaFormycon AGPhase 3
22
6-Thio-2'-Deoxyguanosine + CemiplimabMAIA BiotechnologyPhase 2
32
6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine aloneMAIA BiotechnologyPhase 3
37
pemetrexed + cisplatinEli LillyPhase 2
27
gemcitabine + carboplatin + cisplatinEli LillyPhase 2
35
CetuximabEli LillyPhase 1
29
pemetrexed + docetaxelEli LillyPhase 3
40
enzastaurin + pemetrexed + docetaxel + carboplatinEli LillyPhase 2
35
PemCarbo + Pem onlyEli LillyPhase 3
36
TNG456 + abemaciclibEli LillyPhase 1/2
39